Most Searched, Wednesday October 29, 2025 – Crystal Equity Research

Most searched small-cap stocks, Wed Oct 29th - #IOVA #JBLU #RR #ONDS #JAMF #RXRX #ETNB #DVLT #BITF #FUBO #DNN #BBAI #WRD #OBE #MGNX #IQ #CMBM #CAAS #BORR #AEVA - More: crystalequityresearch.com/most-searche... - #smallcap

#ETNB and today #AKRO both aquired, now only #VKTX left.
Long

BREAKING NEWS: ( NASDAQ: #ETNB ) Peer Perform Recommendation Issued On ETNB By Wolfe Research

Most Searched, Thursday September 18, 2025 – Crystal Equity Research

Most searched small-cap stocks, Thu Sept 18th - #REPL #HIVE #ONDS #QUBT #RR #LAES #ETNB #LASE #RCAT #WOLF #TLRY #SBET #PTEN #LUNR #GALT #CERS #BTCS #BREA #BBAI #ADAP - More: crystalequityresearch.com/most-searche... - #smallcap

Trending Now: INTC, NVDA, CRWD & 89bio Soar — Big Deals & Bi Trending Now: INTC, NVDA, CRWD & 89bio Soar — Big Deals & Big Breakouts Driving Talk Today’s Trending Movers & Social Buzz 1. Intel (INTC) Price Move: Surged ~23-25%, its biggest one-day rise since

#stockMarket #investing Trending stocks today 18th of Sept #INTC +25%, #NVDA + 4%, #CRWD +13%, #ETNB +85% 📈📉 www.stocks2buynow.com/group/trendi...

BREAKING NEWS: ( NASDAQ: #ETNB ) US Companies Moving the Markets, Morning edition <br>Thu, Sep 18, 2025 as of 10.00 am ET

JUST IN: ( NASDAQ: #ETNB ) Morning Market Surge: Innovation, M&A, and Strategic Expansion Drive Early Action

$3.5 Billion Biotech Deal: Roche Acquires 89bio for Breakthrough MASH Treatment Pegozafermin Roche to acquire 89bio for $14.50/share cash plus $6.00 CVR, totaling $3.5B. Deal adds pegozafermin MASH treatment to portfolio. Includes milestone payments tied to sales targets of $3B-$4B by 2035.

#ETNB 89bio, Inc. Announces Agreement to be Acquired by Roche

www.stocktitan.net/news/ETNB/89bio-inc-anno...

89bio (ETNB) Q2 R&D Jumps 131% | The Motley Fool

#ETNB #bbe94a57-57e9-4ccc-8c2d-43426249c736 #data-news

Origin | Interest | Match

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CRM, #OSCR, #ETNB, #PLUG, #SRPT

#OptionFlow #OptionsTrading #Trading

BREAKING NEWS: ( NASDAQ: #ETNB ) How To Trade (ETNB)

BREAKING NEWS: ( NASDAQ: #ETNB ) (ETNB) Long Term Investment Analysis

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Tue May 20th - #XNEX #TELA #SBC #QIPT #PANL #MNMD #LAES #KOSS #HOWL #VANI #GAN #FENC #ETNB #CMPS #ARQQ #XYF #VCSA #PGRE #NGL - More: crystalequityresearch.com/SmCpStr/ - #smallcap

89bio Reports First Quarter 2025 Financial Results and Corporate Updates 89bio (ETNB) reported Q1 2025 financial results and provided updates on its clinical programs. The company's lead drug candidate pegozafermin is advancing in multiple Phase 3 trials. The ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis trials for MASH treatment are expected to report topline data in 1H 2027 and 2028, respectively. The Phase 3 ENTRUST trial for severe hypertriglyceridemia is fully enrolled with data expected in Q1 2026. Financially, 89bio ended Q1 2025 with $638.8 million in cash and equivalents, bolstered by a $287.5 million follow-on offering. The company reported a net loss of $71.3 million for Q1 2025, compared to $51.7 million in Q1 2024, primarily due to increased R&D expenses for Phase 3 programs. R&D expenses were $64.4 million, up from $47.4 million year-over-year.

#ETNB 89bio Reports First Quarter 2025 Financial Results and Corporate Updates

www.stocktitan.net/news/ETNB/89bio-reports-...

89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates 89bio (ETNB) reported financial results for Q4 and full year 2024, highlighting progress in its clinical trials. The company's Phase 3 ENLIGHTEN trials for MASH patients continue advancing, with topline histology data expected in 1H 2027 for non-cirrhotic patients and 2028 for cirrhotic patients. The Phase 3 ENTRUST trial in severe hypertriglyceridemia completed enrollment with 369 patients, with topline data now expected in Q1 2026.Financial highlights include cash position of $440.0 million as of December 31, 2024, with additional gross proceeds of $287.5 million from a follow-on offering in Q1 2025. R&D expenses increased to $345.0 million for 2024, up from $122.2 million in 2023. The company reported a net loss of $367.1 million for 2024, compared to $142.2 million in 2023.

#ETNB 89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

www.stocktitan.net/news/ETNB/89bio-reports-...

89bio Secures Quarter-Billion Dollar War Chest: Major Financial Institutions Back Massive Capital Raise 89bio announces significant capital raise through 21.7M share offering and 6.9M pre-funded warrants, with Goldman Sachs, Leerink, and BofA leading the underwriting.

#ETNB 89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/ETNB/89bio-inc-anno...

89bio Announces $250M Public Offering to Advance Pegozafermin Development 89bio launches major capital raise with top-tier underwriters, seeking funds for pegozafermin clinical development and manufacturing expansion. Optional $37.5M increase.

#ETNB 89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/ETNB/89bio-inc-anno...

2/ If not stat sig, but showing improvement consistent w/36w results, I'll stick my neck out that #AKRO Stk reaction won't be anything like Oct'23. Either way, imo this data will be very telling for the whole program, and how EFX may ultimately compete w/ #MDGL #ETNB

1/ The Oct '23 36w readout of EFX Ph2b crushed #AKRO stk despite what looked like pretty impressive data given the short time to readout & the tough pts pop it's tackling. The 96w readout is coming in Feb. If stat sign - despite study not being powered for that - stk cud/shud fly... #ETNB #MDGL

89bio Provides Business Update and Outlook for 2025 89bio (ETNB) provided a corporate update and business outlook for 2025, highlighting key developments in their clinical programs. The company completed enrollment in the Phase 3 ENTRUST trial for severe hypertriglyceridemia (SHTG), with topline 26-week data expected in H2 2025. The Phase 3 ENLIGHTEN program for MASH (metabolic dysfunction-associated steatohepatitis) continues patient enrollment across both trials.The company strengthened its financial position with $440 million in cash and equivalents as of December 31, 2024, bolstered by a $143.8 million equity offering and a credit facility up to $150 million with K2 HealthVentures. 89bio received regulatory feedback from FDA and EMA regarding pegozafermin's marketing requirements and enhanced its leadership team with four industry veterans in key positions.

#ETNB 89bio Provides Business Update and Outlook for 2025

www.stocktitan.net/news/ETNB/89bio-provides...

#ETNB 89bio to Participate in the 7th Annual Evercore HealthCONx Conference

www.stocktitan.net/news/ETNB/89bio-to-parti...